Drugs / HRS-2189
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07639905 | Jun → Aug 2026 | cancer | Shandong Suncadia Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05851092 | May 2023 → Dec 2025 | cancer | Shandong Suncadia Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06974929 | May 2025 → Dec 2026 expected | breast cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06679036 | Jan 2025 → Oct 2026 expected | breast cancer | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06568094 | Sep 2024 → Dec 2026 expected | prostate cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07061210 | Jul 2025 → Oct 2026 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06738745 | Dec 2024 → Jan 2027 expected | metastatic prostate carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-2189 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07061210 ↗ |
| Route | Oral | “HRS-2189 tablet, oral.” NCT07639905 ↗ |